The FDA approval of mirdametinib (Gomekli) marked a key milestone for adult patients with neurofibromatosis type 1 (NF1)–associated plexiform neurofibromas (PNs), with an agent now indicated for the treatment of this population for the first time, according to Justin T. Jordan, MD, MPH, FAAN.

It can spawn tumors throughout the nervous system and bone deformities that riddle the whole body with pain. One of the most common rare diseases in the world, the genetic condition neurofibromatosis type 1, or NF1, can cause a wide spectrum of mild to severe symptoms—all stemming from a single mutation on a solitary gene: the NF1 gene on chromosome 17.

The NF Network is excited to introduce an invaluable educational lunch and learn event to the Georgia community! On September 6, seize the opportunity to connect with fellow NF families while enjoying a complimentary lunch at this insightful event! Join us at the Marietta History Center, located at Marietta Market Square, 1 Depot St, Marietta. Kick off your day by exploring the popular Farmer's Market, then gather for an enlightening session featuring three expert NF speakers.

Kaitlyn, who adores baby dolls, received a Real Care doll named Lilly a few years ago. After high school, she dreams of working as a teacher's assistant, despite the challenges of managing her SSI services. Driven by a desire to give back, Kaitlyn began bringing Lilly to retirement communities, setting up monthly Baby Doll Therapy sessions at The Villages in Germantown with the help of her aide, Lori Gresham.